The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bychkova N.M.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow, Russia

Khmelevsky E.V.

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia, Moscow, Russian Federation

Current approaches to radiotherapy for skeletal metastastic lesions

Authors:

Bychkova N.M., Khmelevsky E.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2019;8(4): 295‑302

DOI: 10.17116/onkolog20198041295

Read: 22955 times

Download PDF (RU)
Contact the author
Table of contents

CURRENT APPROACHES TO RADIOTHERAPY FOR SKELETAL METASTASTIC LESIONS
CURRENT APPROACHES TO RADIOTHERAPY FOR SKELETAL METASTASTIC LESIONS

To cite this article:

Bychkova NM, Khmelevsky EV. Current approaches to radiotherapy for skeletal metastastic lesions. P.A. Herzen Journal of Oncology. 2019;8(4):295‑302. (In Russ.)
https://doi.org/10.17116/onkolog20198041295

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The choice of radiotherapy dose fractionation regi­men for grade 4 gliomas depe­nding on the status of MGMT. P.A. Herzen Journal of Onco­logy. 2025;(1):13-18
Radiation therapy with focal dose esca­lation in the treatment of glioblastoma. P.A. Herzen Journal of Onco­logy. 2025;(2):64-69
Proton therapy of skull base chordoma. P.A. Herzen Journal of Onco­logy. 2025;(5):64-67
Problems of pregnancy planning and gestation in patients with diffuse toxic goiter after radiotherapy. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):82-87
Lean mana­gement example at the radiotherapy depa­rtment. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):67-73
Prevention and treatment of dermal toxi­city in children receiving anti-tumor radiation. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):470-480
Hypo­fractionated irra­diation for intracranial meni­ngiomas. Burdenko's Journal of Neurosurgery. 2025;(6-2):21-28
Abstract:

According to autopsy data, the incidence of skeletal metastases is 40—45%. In cancer patients, most cases of pain syndrome are associated with the development of bone metastases. Skeletal metastases complicated by pathological fractures or spinal cord or peripheral nerve compression significantly lower quality of life in patients and still remain an actual problem for oncologists of various specialties. Radiotherapy along with surgical treatment and systemic drug therapy occupies an important place in the treatment of skeletal metastatic lesions. Various local exposure techniques (3D conformal radiation therapy and stereotactic body radiotherapy (SBRT)), as well as systemic radiotherapy with radiopharmaceuticals based on 153Sm, 89Sr, 186Re, 188Re, 177Lu, 90Y, 131I, etc. are applied. The development of radiotherapy technologies expands indications first of all in case of oligometastatic lesions.

Keywords:

bone metastases
radiotherapy

Authors:

Bychkova N.M.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of the Russian Federation, Moscow, Russia

Khmelevsky E.V.

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia, Moscow, Russian Federation

Close metadata

References:

  1. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176.
  2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20):6243-6249. https://doi.org/10.1158/1078-0432.CCR-06-0931
  3. Schulman K, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007;109(11):2334-2342. https://doi.org/10.1002/cncr.22678
  4. Fidler I, Radinsky R. Genetic control of cancer metastasis. J Natl Cancer Inst. 1990;82:160-168.
  5. Suva L, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer. 2009;16:703-713. https://doi.org/10.1677/ERC-09-0012
  6. Suva L, Washam C, Nicholas R, Griffin R. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7(4):208-218. https://doi.org/10.1038/nrendo.2010.227
  7. Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol. 2009;310:71-81. https://doi.org/10.1016/j.mce.2009.07.004
  8. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12(20,Pt2):6213s-6216s. https://doi.org/10.1158/1078-0432.CCR-06-1007
  9. Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control. 2012;19(2):92-101. https://doi.org/10.1177/107327481201900203
  10. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1-2):1-18.
  11. Urch C. The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med. 2004;18(4):267-274. https://doi.org/10.1191/0269216304pm887ra
  12. Chow R, Hoskin P, Hollenberg D, Lam M, Dennis K, Lutz S, Lam H, Mesci A, DeAngelis C, Chan S, Chow E. Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. Ann Palliat Med. 2017;6(2):125-142. https://doi.org/10.21037/apm.2016.12.04
  13. Hess G, Barlev A, Chung K, Hill JW, Fonseca E. Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer. Radiat Oncol. 2012;7:68. https://doi.org/10.1186/1748-717X-7-168
  14. Tiwana MS, Barnes M, Kiraly A, Olson RA. Utilization of palliative radiotherapy for bone metastases near end of life in a population-based cohort. BMC Palliat Care. 2016;15:2. https://doi.org/10.1186/s12904-015-0072-5
  15. Medvedev SV, Tkachev SI, Romanov DS, Glebovskaya VV, Timoshkina EV, Valiev AK, Trofimova OP, Burov DA, Safronov DI, Fedoseenko DI, Bychkova NM. Radiotherapy in the treatment of patients with spinal cord compression. Onkologiya. Zhurnal im. P.A. Gertsena. 2017;4(6):46-49. (In Russ.) https://doi.org/10.17116/onkolog20176446-49
  16. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol. 2012;24(2):112-124. https://doi.org/10.1016/j.clon.2011.11.004
  17. Smith HS. Painful osseous metastases. Pain Physician. 2011;14:E373-E405. https://doi.org/10.3978/j.issn.2224-5820.2012.02.03
  18. Price P, Hoskins PJ, Easten D, Austin D, Palmer SG, Yarnold JR. Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bone metastases. Radiother Oncol. 1986;6(4):247-255.
  19. Park HC, Seong J, An JH, Kim J, Kim UJ, Lee BW. Alteration of cancer pain-related signals by radiation: proteomic analysis in an animal model with cancer bone invasion. Int J Radiat Oncol Biol Phys. 2005;61(5):1523-1534. https://doi.org/10.1016/j.ijrobp.2004.12.070
  20. Vit JP, Ohara PT, Tien DA, Fike JR, Eikmeier L, Beitz A, Wilcox GL, Jasmin L. The analgesic effect of low dose focal irradiation in a mouse model of bone cancer is associated with spinal changes in neuro-mediators of nociception. Pain. 2006;120(1):188-201. https://doi.org/10.1016/j.pain.2005.10.033
  21. Popovic M, den Hartogh M, Zhang L. Review of international patterns of practice for the treatment of painful bone metastases with palliative radiotherapy from 1993 to 2013. Radiother Oncol. 2014;111(1):11-17. https://doi.org/10.1016/j.radonc.2014.01.015
  22. Meeuse JJ, van der Linden YM, van Tienhoven G, Gans RO, Leer JW, Reyners AK. Efficacy of radiotherapy for painful bone metastases during the last 12 weeks of life: results from the Dutch Bone Metastasis Study. Cancer. 2010;116(11):2716-2725. https://doi.org/10.1002/cncr.25062
  23. Majumder D, Chatterjee D, Bandyopadhyay A, Mallick SK, Sarkar SK, Majumdar A. Single fraction versus multiple fraction radiotherapy for palliation of painful vertebral bone metastases: a prospective study. Indian J Palliat Care. 2012;18(3):202-206. https://doi.org/10.4103/0973-1075.105691
  24. Howell DD, James JL, Hartsell WF, Suntharalingam M, Machtay M, Suh JH, Demas WF, Sandler HM, Kachnic LA, Berk LB. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases - equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14. Cancer. 2013;119(4):888-896. https://doi.org/10.1002/cncr.27616
  25. Gutiérrez Bayard L, Salas Buzón Mdel C, Angulo Paín E, de Ingunza Barón L. Radiation therapy for the management of painful bone metastases: Results from a randomized trial. Rep Pract Oncol Radiother. 2014;19(6):405-411. https://doi.org/10.1016/j.rpor.2014.04.009
  26. Abeer Hussien Anter. Single fraction versus multiple fraction radiotherapy for treatment of painful bone metastases: a prospective study; Mansoura experience. Forum Clin Oncol. 2015;6(2):8-13. https://doi.org/10.1515/fco-2015-0007
  27. Hoskin P, Rojas A, Fidarova E, Jalali R, Mena Merino A, Poitevin A, Oucrif S, Abdelwahab S, Kochbati L, Plieskiene A, et al. IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastases. Radiother Oncol. 2015;116(1):10-14. https://doi.org/10.1016/j.radonc.2015.05.008
  28. Rutter CE, Yu JB, Wilson LD,Park HS. Assessment of national practice for palliative radiation therapy for bone metastases suggests marked underutilization of single-fraction regimens in the United States. Int J Radiat Oncol Biol Phys. 2015;91(3):548-555. https://doi.org/10.1016/j.ijrobp.2014.10.045
  29. Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, Wong R, Hahn C. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(1):4—12. https://doi.org/10.1016/j.prro.2016.08.001
  30. Chow R, Hoskin P, Chan S, Mesci A, Hollenberg D, Lam, DeAngelis C, Chow E. Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review. Radiother Oncol. 2017;122(3):323-331. https://doi.org/10.1016/j.radonc.2016.12.031
  31. Sheehan JP, Shaffrey CI, Schlesinger D, Williams BJ, Arlet V, Larner J. Radiosurgery in the treatment of spinal metastases: tumor control, survival, and quality of life after helical tomotherapy. Neurosurgery. 2009;65(6):1052-1061. https://doi.org/10.1227/01.NEU.0000359315.20268.73
  32. Nikolajek K, Kufeld M, Muacevic A, Wowra B, Niyazi M, Ganswindt U. Spinal radiosurgery — efficacy and safety after prior conventional radiotherapy. Radiat Oncol. 2011;6:173. https://doi.org/10.1186/1748-717X-6-173
  33. Ahmed KA, Stauder MC, Miller RC, Bauer HJ, Rose PS, Olivier KR, Brown PD, Brinkmann DH, Laack NN. Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys. 2012;82(5):e803-e809. https://doi.org/10.1016/j.ijrobp.2011.11.036
  34. Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning I, Liu P, Allen PK, Azeem SS, Brown PD, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol. 2012;13(4):395-402. https://doi.org/10.1016/S1470-2045(11)70384-9
  35. Jhaveri PM, Teh BS, Paulino AC, Blanco AI, Lo SS, Butler EB, Amato RJ. A dose-response relationship for time to bone pain resolution after stereotactic body radiotherapy (SBRT) for renal cell carcinoma (RCC) bone metastases. Acta Oncol. 2012;51(5):5848. https://doi.org/10.3109/0284186X.2011.652741
  36. Napieralska A, Miszczyk L, Tukiendorf A, Stąpór-Fudzińska M. The results of treatment of prostate cancer bone metastases after CyberKnife radiosurgery. Ortop Traumatol Rehabil. 2014;16(3):339-349. https://doi.org/10.5604/15093492.1112535
  37. Księżniak-Baran D, Blamek S, Roch-Zniszczoł A, Stąpór-Fudzińska M, Miszczyk L. Evaluation of efficacy and safety of robotic stereotactic body radiosurgery and hypofractionated stereotactic radiotherapy for vertebral metastases. Contemp Oncol (Pozn). 2015;19(4):327-332. https://doi.org/10.5114/wo.2015.53371
  38. Mantel F, Glatz S, Toussaint A, Flentje M, Guckenberger M. Long-term safety and efficacy of fractionated stereotactic body radiation therapy for spinal metastases. Strahlenther Onkol. 2014;190(12):1141-1148. https://doi.org/10.1007/s00066-014-0706-1
  39. Erler D, Brotherston D, Sahgal A. Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases. Radiother Oncol. 2018;127(2):304-309. https://doi.org/10.1016/j.radonc.2018.03.030
  40. Liepe K, Krylov VV, Kochetova TYu. Radionuclide therapy for bone metastases by drugs based on Re-188. Voprosy onkologii. 2016;62(4):401-409. (In Russ.)
  41. Krylov VV, Tsyb AF, Drozdovskii BYa. Radionuclide therapy for bone metastases. Meditsinskaya radiologiya i radiatsionnaya bezopasnost’. 2006;51(3):65-74. (In Russ.)
  42. Kaprin AD, Kostin AA, Leont’ev AV, Lazutina TN, Pylova IV, Dushakova LV. Possibilities of systemic radionuclide therapy in palliative treatment of patients with metastatic bones disease. Issledovaniya i praktika v meditsine. 2014;1(1):57-61. (In Russ.) https://doi.org/10.17709/2409-2231-2014-1-57-61
  43. Zenda S, Nakagami Y, Toshima M, Arahira S, Kawashima M, Matsumoto Y, Kinoshita H, Satake M, Akimoto T. Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases. Int J Clin Oncol. 2014;19(4):739-743. https://doi.org/10.1007/s10147-013-0597-7
  44. Handkiewicz-Junak D, Poeppel TD, Bodei L, Aktolun C, Ezziddin S, Giammarile F, Delgado-Bolton RC, Gabriel M. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging. 2018;45(5):846-859. https://doi.org/10.1007/s00259-018-3947-x
  45. Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007;28(8):623-630. https://doi.org/10.1097/MNM.0b013e32825a6adc
  46. Ezziddin S, Sabet A, Heinemann F, Yong-Hing CJ, Ahmadzadehfar H, Guhlke S, Höller T, Willinek W, Boy C, Biersack HJ. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2011;52(8):1197-1203. https://doi.org/10.2967/jnumed.111.090373
  47. Skóra T, Kowalska T, Zawiła K. Effectiveness of radioisotope therapy in bone metastases, based on personal experience. Wspolczesna Onkol. 2012;16(3):201-205. https://doi.org/10.5114/wo.2012.29284
  48. Lange R, Overbeek F, de Klerk JM, Pasker-de Jong PC, van den Berk AM, Ter Heine R, Rodenburg CJ, Kooistra A, Hendrikse NH, Bloemendal HJ. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Nuklearmedizin. 2016;55(5):188-195. https://doi.org/10.3413/Nukmed-0828-16-05
  49. Baba K, Kaida H, Hattori C, Muraki K, Kugiyama T, Fujita H, Ishibashi M. Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases. Hell J Nucl Med. 2018;21(1):15-23.
  50. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738-746. https://doi.org/10.1016/S1470-2045(14)70183-4
  51. Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, et al. Radium-223 International Early Access Program Investigators. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17(9):1306-1316. https://doi.org/10.1016/S1470-2045(16)30173-5
  52. Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patientswith bone-dominant disease. Breast Cancer Res Treat. 2014;145(2):411-418. https://doi.org/10.1007/s10549-014-2939-1
  53. Takalkar A, Paryani B, Adams S, Subbiah V. Radium-223 dichloride therapy in breast cancer with osseous metastases. BMJ Case Rep. 2015;2015. pii: bcr2015211152. https://doi.org/10.1136/bcr-2015-211152
  54. Zustovich F, Barsanti R. Targeted α Therapies for the treatment of bone metastases. Int J Mol Sci. 201728;19(1). pii: E74. https://doi.org/10.3390/ijms19010074
  55. Ogawa K, Ishizaki A. Well-designed bone−seeking radiolabeled compounds for diagnosis and therapy of bonemetastases. Biomed Res Int. 2015;2015:676053. https://doi.org/10.1155/2015/676053
  56. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41(7):1280-1292. https://doi.org/10.1007/s00259-014-2713-y
  57. Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, et al. Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016;196(2):382-391. https://doi.org/10.1016/j.juro.2016.02.2969
  58. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825-833. https://doi.org/10.1016/S1470-2045(18)30198-0
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.